Impact of gestational age and birth weight on amikacin clearance on day 1 of life

Clin J Am Soc Nephrol. 2009 Nov;4(11):1774-8. doi: 10.2215/CJN.02230409. Epub 2009 Aug 27.

Abstract

Background and objectives: Intrauterine growth restriction (IUGR) and prematurity are associated with a low nephron endowment. It can therefore be expected that neonates who are born premature and/or after IUGR have a lower GFR. Measurement of GFR in neonates is difficult, but the clearance of amikacin has been proven to be a reliable marker. We hypothesized that amikacin clearance is lower after IUGR or premature birth as a marker of low nephron endowment.

Design, setting, participants, & measurements: Amikacin clearance was retrospectively analyzed in 161 neonates who received amikacin within the first 24 h of life. Using the MW/Pharm computer program, a population one-compartment model was calculated. The mean population pharmacokinetic parameters were individualized for each patient according to the maximum a posteriori Bayesian fitting method and provided the amikacin clearance.

Results: Our results show that birth weight z score and gestational age are correlated with the clearance of amikacin (partial correlation coefficient 0.159, P = 0.046, and 0.396, P < 0.001, respectively), after correction for other factors.

Conclusions: We conclude that renal clearance on the first day of life is lower in neonates with a lower gestational age and/or birth weight z score. This indicates that both prematurity and IUGR impair GFR on the first day of life.

MeSH terms

  • Amikacin / pharmacokinetics*
  • Anti-Bacterial Agents / pharmacokinetics*
  • Birth Weight
  • Female
  • Fetal Growth Retardation / metabolism*
  • Gestational Age
  • Glomerular Filtration Rate
  • Humans
  • Infant, Newborn
  • Infant, Premature / metabolism*
  • Kidney / abnormalities*
  • Kidney / metabolism
  • Kidney Function Tests / methods*
  • Kidney Function Tests / standards
  • Male
  • Nephrons / abnormalities
  • Nephrons / metabolism
  • Reproducibility of Results
  • Retrospective Studies

Substances

  • Anti-Bacterial Agents
  • Amikacin